S256: TABELECLEUCEL FOR EBV-DRIVEN POST-TRANSPLANT LYMPHOPROLIFERATIVE DISEASE FOLLOWING ALLOGENEIC HEMATOPOIETIC CELL OR SOLID ORGAN TRANSPLANT AFTER FAILURE OF RITUXIMAB ± CHEMOTHERAPY (ALLELE)

• S. Prockop, MD,
• A. Beitinjaneh, MD,
• S. Choquet, MD,
• S. Dahiya, MD,
• R. Dinavahi, MD,
• R. Farah, MD,
• L. Gamelin, MD, PhD,
• A. Ghobadi, MD,
• A. Mehta,
• P. Nayak, MD,
• R. Reshef, MD,
• G. Satyanarayana, MD,
• P. Stiff, MD,
• W. Ye, PhD,
• K. M. Mahadeo, MD, MPH

Affiliations

S. Prockop, MD

1 Boston Children’s Hospital/Dana Farber Cancer Institute, Boston

A. Beitinjaneh, MD

2 University of Miami/Jackson Memorial Hospital, Miami, United States of America

S. Choquet, MD

3 Sorbonne Université, Hôpital de la Pitié-Salpêtrière, Paris, France

S. Dahiya, MD

4 University of Maryland School of Medicine, Baltimore

R. Dinavahi, MD

5 Atara Biotherapeutics, Thousand Oaks

R. Farah, MD

6 UPMC Hillman Cancer Center, Pittsburgh

L. Gamelin, MD, PhD

5 Atara Biotherapeutics, Thousand Oaks

A. Ghobadi, MD

7 Washington University, Division of Oncology, St. Louis

A. Mehta

5 Atara Biotherapeutics, Thousand Oaks

P. Nayak, MD

8 Atara Biotherapeutics, South San Francisco

R. Reshef, MD

9 Columbia University Medical Center, New York

G. Satyanarayana, MD

10 Ingram Cancer Center, Vanderbilt Health, Nashville

P. Stiff, MD

11 Loyola University Medical Center, Chicago

W. Ye, PhD

8 Atara Biotherapeutics, South San Francisco

K. M. Mahadeo, MD, MPH

12 MD Anderson Cancer Center, Houston, United States of America